Catalyst Brief

← Calendar

Readoutin 45d

AstraZeneca — Durvalumab

Phase 3 primary completion: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer.

Date
Jan 2027
Type
Readout
Indication
Non-Small Cell Lung Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from AstraZeneca

  1. May2027
  2. Feb2027
  3. Feb2027
  4. Feb2027
  5. Jan2027
    Readoutin 45d
    AstraZeneca — Dato-DXd
    Phase 3 primary completion: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.